FATE
FATE THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$2.08
+1.78%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.05
From 52W high−33.23%
Volume428027.00
Market cap$248.80M
P/E (TTM)—
P/S (TTM)38.3x
Div yield—
Key dataNov 4, 2026
Open
$2.05
From 52W high
−33.23%
Volume
428027.00
Market cap
$248.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
44.3
MomentumView details →
1D Return
+1.78%
YTD Return
+108.60%
SummaryUpdated Jun 1, 2026
Fate Therapeutics, Inc. (NASDAQ:FATE) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in San Diego, California. The company went public in 2013 and has established itself as a pioneer in developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). Fate Therapeutics focuses on creating programmed cellular treatments for cancer and autoimmune disorders, representing a cutting-edge approach to cell therapy that could potentially transform how these diseases are treated.
Similar companies
Latest newsMore news →
FATE THERAPEUTICS INC presented updated Phase 1 clinical data for FT819 in patients with systemic lupus erythematosus and lupus nephritis, reporting 100% renal response at Month 6 and an approximately 50% mean reduction in proteinuria among patients treated with the bendamustine conditioning regimen.9d agoFate Therapeutics reported a Q2 2026 loss of $0.25 per share, beating the Zacks Consensus Estimate of a $0.28 loss and improving from a $0.29 loss a year earlier.83d ago